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4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N -nitrosonornicotine (NNN) are tobacco-speciﬁc nitrosamines
present in tobacco products and smoke. Both compounds are carcinogenic in laboratory animals, generating tumors at sites
comparable to those observed in smokers. These Group 1 human carcinogens are metabolized to reactive intermediates that
alkylate DNA. This paper focuses on the DNA pyridyloxobutylation pathway which is common to both compounds. This DNA
route generates 7-[4-(3-pyridyl)-4-oxobut-1-yl]-2 -deoxyguanosine, O2-[4-(3-pyridyl)-4-oxobut-1-yl]-2 -deoxycytosine, O2-[4-
(3-pyridyl)-4-oxobut-1-yl]-2 -deoxythymidine, and O6-[4-(3-pyridyl)-4-oxobut-1-yl]-2 -deoxyguanosine as well as unstable
adducts which dealkylate to release 4-hydroxy-1-{3-pyridyl)-1-butanone or depyriminidate/depurinate to generate abasic sites.
There are multiple repair pathways responsible for protecting against the genotoxic eﬀects of these adducts, including adduct
reversal as well as base and nucleotide excision repair pathways. Data indicate that several DNA adducts contribute to the overall
mutagenic properties of pyridyloxobutylating agents. Which adducts contribute to the carcinogenic properties of this pathway are
likely to depend on the biochemistry of the target tissue.
1.Introduction
Tobacco use has been linked to a variety of human cancers,
including lung, oral cavity, esophagus, pharynx, larynx,
urinary bladder, pancreas, and liver cancers [1]. Lung cancer
alone is responsible for the deaths of 1.3 million people
annually worldwide [2]. It is the leading cause of cancer
deaths in the United States, with 80%–90% of this cancer
associated with tobacco use [1]. Environmental tobacco
smoke (second-hand smoke) has also been associated with
human lung cancer but the risks are signiﬁcantly lower than
those associated with smoking [1].
There are more than 5000 identiﬁed chemicals present in
cigarette smoke [1, 3–5]. More than 60 of these compounds
are demonstrated chemical carcinogens in animal models [1,
3, 4, 6]. An important group of tobacco carcinogens are the
tobacco-speciﬁcnitrosamines.Thesecompoundsareformed
from tobacco alkaloids like nicotine during the curing
process of tobacco [7]. 4(Methylnitrosamino)-1-(3pyridyl)-
1-butanone (NNK) and N -nitrosonornicotine (NNN) are
twoofthemostpotenttobacco-speciﬁcnitrosaminespresent
in tobacco products and smoke [8]. Both compounds are
carcinogenic in laboratory animals, generating tumors at
sites comparable to those observed in smokers [8]. NNK is
a potent lung carcinogen, which also induces liver and nasal
tumors [9–11]. This compound induces lung adenocarci-
nomas in rodents at lifetime doses that are comparable to
those experienced by smokers [8]. Adenocarcinoma is now
the most common type of lung cancer observed in humans,
having surpassed squamous cell carcinoma [12–16]. This
shift in histology has been attributed not to improvements
in diagnoses but rather to changing cigarette design, which
has changed smoking behavior resulting in increased uptake
of tobacco-speciﬁc nitrosamines by smokers [14]. Metabolic
productsofNNKhavebeendetectedinurineofsmokersand
individuals exposed to second-hand smoke, indicating that
humans are exposed to and metabolize this carcinogen [17–
20]. NNN is carcinogenic to the esophagus, nasal cavity, and
respiratory tract in laboratory animals [8]. This nitrosamine
is present in higher amounts than any other esophageal2 Journal of Nucleic Acids
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Scheme 1: Pathways of bioactivation of NNK, NNN, and model pyridyloxobutylating agent, NNKOAc.
carcinogen in tobacco smoke [8]. It and/or its glucuronide
conjugate have been detected in the urine and toenails of
smokers and smokeless tobacco users [21–25]. Based on
animal studies, NNK and NNN are listed as Group 1 human
carcinogens by the International Agency for Cancer Research
[6, 8].
NNK and NNN require metabolism to exert their toxico-
l o g i c a lp r o p e r t i e s[ 8]. NNK-induced carcinogenesis requires
cytochrome P450 catalyzed metabolic activation to DNA
reactive metabolites [26]. NNK is metabolized to either a
methylatingorapyridyloxobutylatingagent(Scheme 1).The
methylation pathway generates well-characterized methyl
DNA adducts, such as 7-methylguanine (7-mG), O6-
methylguanine (O6-mG), and O4-methylthymidine (O4-
mT) [27–31]. The dominant mutagenic adduct is O6-mG
[32, 33]. The repair mechanisms and genotoxic properties
of this adduct have been extensively reviewed [34–37]a n d
will not be a focus of this paper. The formation, repair, and
genotoxic properties of the pyridyloxobutyl adducts will be
discussed below.
NNN also has two pathways to form DNA adducts,
2 -a n d5  -hydroxylation [8]. (S)-NNN, the dominant
enantiomer in tobacco products [38], undergoes primarily
2 -hydroxylation whereas (R)-NNN undergoes both 2 -
and 5 -hydroxylation [39]. 2 -Hydroxylation generates the
same pyridyloxobutylating agent as methyl hydroxylation
of NNK (Scheme 1). 5 -Hydroxylation generates a reactive
metabolite that can also alkylate DNA (Scheme 1)[ 40, 41].
However, no data exist for the levels of these adducts in
vivo. For the purpose of this paper, we will focus on the
pyridyloxobutylation pathway.
2. Structure of PyridyloxobutylDNA Adducts
Thepyridyloxobutylation pathwayleadsto avariety ofaddu-
cts, four of which have been recently identiﬁed (Scheme 2).
They are 7-[4-(3-pyridyl)-4-oxobut-1-yl]-2 -deoxyguano-
sine (7-pobdG) [42], O2-[4-(3-pyridyl)-4-oxobut-1-yl]-2 -
deoxycytosine (O2-pobdC) [43], O2-[4-(3-pyridyl)-4-oxo-
but-1-yl]-2 -deoxythymidine (O2-pobdT) [43], and O6-[4-
(3-pyridyl)-4-oxobut-1-yl]-2 -deoxyguanosine (O6-pobdG)
[42–44]. Both 7-pobdG and O2-pobdC readily release the
corresponding nucleobases, 7[4-(3-pyridyl)-4-oxobut-1-yl]-
guanine (7-pobG) and O2-[4-(3-pyridyl)-4-oxobut-1-yl]-
cytosine (O2-pobC), respectively, leaving behind an abasic
site [42, 43]. In addition, some pyridyloxobutyl DNA
adducts are unstable and dealkylate to release 4-hydroxy-1-
(3-pyridyl)-1-butanone (HPB) (Scheme 2)[ 31, 45]. HPB-
releasing adducts include O2-pobdC [43]a n d7 - p o b d G[ 42].
Quantitation of the speciﬁc pyridyloxobutyl DNA adducts
in calf thymus DNA treated with a model pyridyloxobuty-
lating agent, 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNKOAc, Scheme 1), demonstrates that HPB-
releasing adducts are the major adducts present in pyridy-
loxobutylated DNA [46]. They represent approximately 65%
of the total adducts formed. The relative levels of the
speciﬁc adducts making up the remainder are 7-pobG >
O6-pobdG >O 2-pobdT ≥ O2-pobC.
Conﬂicting evidence exists for the formation of phos-
phate adducts in pyridyloxobutylated DNA. HPB is not
released from pyridyloxobutylated DNA when heated under
basic conditions [45]. This observation is not consistent
with the presence of pyridyloxobutyl phosphate esters.
However, the 3 -termini of NNKOAc-induced strand breaksJournal of Nucleic Acids 3
are resistant to 32P-endlabeling in the presence of T4 DNA
polymerase even after incubating with endonuclease IV
which removes 3 -phosphate or 3 -phosphoglycolate groups
[47]. This observation suggests that there may be an adduct
on the 3 -phosphate group. However, the nucleobase adduct,
O6-pobdG, has been reported to inhibit 3 -exonuclease
degradationofDNA[48].Therefore,itispossiblethisadduct
orotherpyridyloxobutylDNAadductsinhibitsendonuclease
IV as well. Also supporting the formation of pyridyloxobutyl
phosphate adducts is the detection of a 4-(3-[5-3H]pyridyl)-
4-hydroxy-2-butylcobalam complex when enzymatic digests
of DNA from [5-3H]NNK-treated animals were reacted with
cob(I)alamin followed by sodium borohydride [49]. This
reaction product accounted for up to 22% of the total
pyridyloxobutyl adducts detected. Cob(I)alamin selectively
reacts with alkyl phosphate adducts [50]. However, the
p y r i d y l o x o b u t y lg r o u pm i g h tb em o r er e a c t i v ew i t ht h i s
reagent than a simple alkyl group and the product may
be formed from adducts other than alkyl phosphates. This
possibility requires further testing.
3. Levels of PyridyloxobutylDNA Adducts in
NNK- or NNN-Treated Rodents
P y r i d y l o x o b u t y lD N Aa d d u c t sh a v eb e e no b s e r v e di nD N A
isolated from the tissues of NNK- or NNN-treated animals.
HPB-releasing adducts have been detected in target tissues
a n dh a v eb e e ns h o w nt op e r s i s t[ 8, 52]. They have also
been linked to tumor formation in the rat [53]. More
recent studies have reported the levels of speciﬁc adducts
in target and nontarget tissues of NNK- or NNN-treated
rodents. One of the ﬁrst studies demonstrated that O6-
pobdG was present at very low levels in lung and liver
DNA from [5-3H]NNK-treated A/J mice [54]. Subsequent
experiments have employed sensitive LC-MS/MS assays [55,
56] for their detection of DNA from in vivo sources. Table 1
displays the levels of pyridyloxobutyl DNA adducts detected
in lung and liver DNA following four subcutaneous doses
of NNK [51]. In this study, the relative adduct distribution
was O2-pobdT ≥ 7-pobG >O 2-pobC   O6-pobdG in
lung DNA and O2-pobdT = 7-pobG ≥ O2-pobC  
O6-pobdG in liver DNA. The levels of 7-pobG, O2-pobC
and O2-pobdT were higher in liver relative to lung DNA
wherease the levels of O6-pobdG were higher in lung relative
to liver. O2-pobdT was also the dominant adduct detected
when rats were chronically treated with a lower dose of
NNK (10ppm in drinking water) (Table 2)[ 57, 58]. The
relative distribution of pyridyloxobutyl DNA adducts was
O2-pobdT > 7-pobG   O2-pobC   O6-pobdG in lung
DNA and O2-pobdT   7-pobG >O 2-pobC in liver DNA;
O6-pobdGwasnotobservedinliverDNAfromtheseanimals
[57]. Pyridyloxobutyl DNA adducts were also observed
in nasal respiratory mucosa, nasal olfactory mucosa, oral
mucosa, and pancreas from NNK-treated rats [59]. The
relative levels of total pyridyloxobutyl DNA adducts is lung >
liver > nasal respiratory mucosa > nasal olfactory mucosa ≈
oral mucosa ≈ pancreas [59].
Similar studies have been performed in NNN-treated
rats [60, 61]. Chronic treatment of F344 rats with (R)-
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Scheme 2: Structures of pyridyloxobutyl DNA adducts and HPB.
NNN or (S)-NNN in the drinking water (10ppm, 1–
20 weeks) led to adduct formation in lungs, liver, nasal
respiratory mucosa, nasal olfactory, and oral mucosa [60,
61]. Target tissues (nasal olfactory, respiratory mucosa, and
esophagus) had the highest levels of pyridyloxobutyl DNA
adducts whereas the nontarget tissues (lung and liver) had
the lowest levels. The enantiomers gave diﬀerent levels of
pyridyloxobutyl DNA adducts in the various tissues. (R)-
NNN produced the highest levels in lung nasal olfactory
and nasal repiratory tissue whereas (S)-NNN generated
higher levels in esophagus, liver, and oral mucosa [60, 61].
These tissue-dependent diﬀerences are likely due to tissue
diﬀerences in the cytochrome P450 enzymes responsible for
the bioactivation of these two enantiomers [60, 61].
As with NNK, O2-pobdT was a major adduct observed
in DNA from various NNN-exposed tissues such as nasal
ofactory mucosa (O2-pobdT > 7-pobG   O2-pobC >
O6-pobdG), respiratory mucosa (O2-pobdT > 7-pobG  
O2-pobC >O 6-pobdG), and oral mucosa (O2-pobdT ≈
7-pobG   O2-pobC >O 6- p o b d G )a sw e l la sl i v e ra n dl u n g
(O2-pobdT   7-pobG ≥ O2-pobC). In the rat esophagus,
7-pobG was the dominant adduct (7-pobG ≥ O2-pobdT ≈
O2-pobC). O6-pobdG was not detected in lung, liver or
esophageal DNA [60].4 Journal of Nucleic Acids
Table 1: Adduct levels in NNK-treated rats [51].
Tissue NNK Dose (mmol/kg)
a 7-pobG O2-pobdT O2-pobC O6-pobG
Mean ±S.D., N = 5 (fmol/mg DNA)
Lung
saline control N.D.
b N.D. N.D. N.D.
0.025 933 ±89 1120 ±66 483 ±36 251 ±26
0.1 1800 ±478 2020 ±483 840 ±169 487 ±101
Liver
saline control N.D. N.D. N.D. N.D.
0.025 3550 ±1600 3530 ±725 2930 ±521 28 ±17
0.1 12200 ±1600 12300 ±1690 7800 ±1680 140 ±25
aAdministered by s.c. injection daily for 4 days.
bN.D.: not detected (detection limit, 3fmol/mg DNA).
4. Formation of PyridyloxobutylDNA
Adducts in Humans
While there is no information regarding the levels of the
four individual pyridyloxobutyl DNA adducts in humans,
HPB-releasing adducts have been detected in human tissue
samples. Levels of these adducts were signiﬁcantly higher
(P<. 0001) in self-reported smokers who had lung cancer
than in self-reported nonsmokers who had lung cancer
(404±258 versus 59±56fmol HPB released/mg DNA, resp.)
[62]. Since HPB-releasing adducts accumulate in normal
lung tissues of lung cancer patients but not in normal
smoking controls [62, 63], these data support a hypothesis
that smokers who accumulate pyridyloxobutyl DNA adducts
may be at increased risk of lung cancer.
5. Repair Pathwaysfor Pyridyloxobutyl
DNA Adducts
DNA adduct repair protects a cell against the toxic and
genotoxic eﬀects of DNA damage. There are multiple
pathways involved in the removal of alkylated DNA bases
generated by reactive alkanediazohydroxides. These include
direct base repair by alkyltransferases and excision of the
DNA damage by base excision repair (BER) or nucleotide
excision repair (NER). Mismatch repair is involved in the
detection and repair of mismatched DNA adducts. Below is
a review of the pathways thought to be involved in the repair
of pyridyloxobutyl DNA damage.
5.1. Adduct Reversal. O6-Alkylguanine DNA alkyltransferase
(AGT) is a suicide protein that repairs O6-alkylguanine
adducts by facilitating the transfer of the alkyl group from
the O6-position of guanine to a cysteine residue in the
p r o t e i n ’ sa c t i v es i t e[ 35]. This alkylation reaction inactivates
the protein and triggers a conformational change [64]w h i c h
leads to its degradation [65]. Consequently, the initial repair
capacity of a cell is determined by its constitutive levels of
AGT.
While O6-pobdG is readily repaired by mammalian
AGTs, it is not a good substrate for the bacterial AGTs ada
and ogt [66]. The ability of AGT orthologs to repair this
bulkyO6-alkylguanineadductislikelydeterminedbythesize
of the protein’s adduct binding site. Rodent AGT has the
largest binding site and repairs O6-pobdG faster than human
AGT which has a smaller binding pocket [66]. The bacterial
AGTs have an even smaller binding pocket, explaining the
inability of these proteins to repair this damage [66]. This
adduct reversal pathway is a major repair pathway for
O6-pobdG in mammalian cells [54, 66, 67].
5.2. Base Excision Repair. Base excision repair (BER) is
another important pathway for the repair of nitrosamine-
derived DNA damage. This pathway is involved in the repair
of single strand breaks, small alkyl guanine damage, and
oxidized DNA bases as well as abasic sites [68, 69]. It is a
multistep process that is initiated when damaged bases are
removed by glycosylases, leaving abasic sites in DNA. The
abasic sites are removed by an endonuclease. The missing
nucleoside is then replaced and ligation occurs. It is likely
that NNK-derived methyl adducts such as 7-methylguanine
and N3-methyladenine are removed by base excision repair
[70]. The ability of pyridyloxobutyl adducts to serve as sub-
strates for BER glycosylases has not been studied. It is possi-
ble that they could serve as substrates since the structurally
similar adduct, O6-butylguanine, appears to be repaired
in part by BER in vivo [71]. It is likely that abasic sites
formed by the depurination/depyrimidination of 7-pobG
and O2-pobC, respectively, are repaired by this pathway.
While little is known about the role of BER in the repair
of pyridyloxobutyl DNA damage, two observations suggest
that BER may be important. First, incubation of lysate
from NNKOAc-treated cells with formamidopyrimidine gly-
cosylase prior to the COMET assay results in a small but
signiﬁcant increase in strand breaks [72]. This observation
indicates that there are pyridyloxobutyl DNA adducts that
are substrates for this glycosylase. Second, loss of XRCC1,
an important scaﬀold protein in BER [73], increases the
mutagenic and toxic eﬀects of NNKOAc [67]. The loss of
this protein does not aﬀect the rate of removal of speciﬁc
pyridyloxobutyl DNA adducts from DNA [67]. However,
the observed increase in toxicity and mutagenicity indicatesJournal of Nucleic Acids 5
Table 2: Comparative DNA adduct levels in lung and liver of F344 rats treated with 10ppm NNK in the drinking water and sacriﬁced at
various intervals [57, 58].
Adduct Levels fmol/mg DNA (mean ±S.D.)
Lung
Week 1 2 5 10 16 20
O6-mG 976 ± 342 1020 ±423 2550 ±263 1020 ±314 729 ±57.5 1910 ±615
O6-pobdG 45 ±7a 50 ±5a 46 ±13a 44 ±14a 34 ±17a 20 ±5a
7-pobG 750 ±95 1180 ±131 1360 ±214a 2220 ±864 1700 ±175a 1060 ±169
O2-pobdT 1080 ±99 2020 ±150 3890 ±648 8260 ±2730a 6720 ±606a 5070 ±1060a
O2-pobC 240 ±23 250 ±18 400 ±87a 730 ±211 810 ±152 940 ±175
Liver
Week 1 2 5 10 16 20
O6-mG 3830 ±865 7120 ±2080 2310 ±946 564 ±250 637 ±59 891 ±379
O6-pobdG n.d. n.d. n.d. n.d. n.d. n.d.
7-pobG 490 ±104a 880 ±182a 1050 ±90 1460 ±625 1170 ± 86a 730 ±225
O2-pobdT 650 ±121a 1230 ±272a 2190 ±174 3740 ±1170a 3540 ±643a 2680 ±643a
O2-pobC 170 ±43a 140 ±25a 240 ±17 580 ±214 350 ±152 490 ±146
n.d., not detected.
aSigniﬁcantly diﬀerent from O6-mG, P<. 05.
that XRCC1 plays an important role in protecting a cell
against the harmful eﬀects of these adducts. Together, these
observations provide evidence for the role of BER in the
repair of pyridyloxobutyl DNA damage.
5.3. Nucleotide Excision Repair. Another important pathway
for the repair of bulky DNA damage is nucleotide excision
repair (NER) [74, 75]. Like BER, NER is a multiprotein
mediated repair pathway. However, in this pathway a whole
section of the damaged DNA strand is removed in several
steps. A new strand is then synthesized by DNA polymerase
using the undamaged strand as a template.
Several pieces of experimental data support the impor-
tance of NER in the repair of pyridyloxobutyl DNA adducts.
In one study, [α-32P]TTP was incorporated into NNKOAc-
treated plasmid DNA when incubated with extracts from
normal human lymphoid cells in an ATP-dependent fashion
[76].Thisactivitywassigniﬁcantlylowerincellextractsfrom
XPA- and XPC-deﬁcient cell lines. XPA and XPC are two
important proteins involved in the initiation of the NER
pathway [74, 75] so their absence signiﬁcantly impacts the
eﬃciency of NER.
A second study examined the removal of speciﬁc
pyridyloxobutyl DNA adducts from DNA in NNKOAc-
treated Chinese hamster ovary cells [67] .T h er a t eo fr e m o v a l
of these adducts was compared between the parental cell
line, AA8, which has functional NER but not AGT, and
UV5 cells which lacks both functional NER [loss of ERCC-2
(XPD)] and AGT [77]. O2-pobdT was the only adduct
whose removal was aﬀected by the loss of ERCC-2. Its
repair was signiﬁcantly slower in the absence of this protein,
suggesting the importance of NER in the removal of this
adduct. Since there were several reports indicating that larger
O6-alkylguanine adducts appear to be preferentially repaired
by nucleotide excision repair [78–82], O6-pobdG repair was
also expected to be reduced in cells lacking NER. However,
O6-pobdG was a poor substrate for this pathway in CHO
c e l l sa sw e l la si na nin vitro human NER repair assay [67].
5.4. Mismatch Repair. Mismatch repair (MMR) is another
important guard against genotoxic stress. In the case of
alkylating agents, this pathway plays a critical role in the
cytotoxicity mediated by these compounds [70, 83–85].
When alkylation is extensive, MMR is involved in triggering
cell death which protects against the mutagenic activity
of these agents. For example, MMR recognizes O6-mG-
T mismatch that occur when AGT is overwhelmed [83].
Unrepaired O6-mG is toxic [36]; absence of MMR removes
the toxicity of methylating agents indicating that this repair
pathway is involved in the mechanism of toxicity [34]. MMR
is initiated when the MSH2-MSH6 heterodimer (MutSα)
binds to the mismatch. The MLH1-PMS2 heterodimer then
bindstoMutSαandtriggersremovalofthemismatchedbase.
In the case of damaged bases, the mismatch process enters a
futile cycle if the adduct is not repaired since polymerases
repeatedly insert the wrong base opposite the modiﬁed
base. This futile cycle can trigger apoptosis [70, 85]. This
futile cycle can be thwarted by homologous recombination,
a multiprotein pathway that uses the sister chromatid as
the template to circumvent replication-halting DNA adducts
[85, 86].
Theroleofmismatchrepairinacell’sresponsetopyridy-
loxobutyl DNA adducts has not been explored. Preliminary
data indicate that O6- p o b d Gm a yn o tb eav e r yt o x i ca d d u c t .
Repair of O6-pobdG by human AGT in bacteria did not
inﬂuence the toxicity of the model pyridyloxobutylating6 Journal of Nucleic Acids
Table 3: Levels of O6-mG and O6-pobG in lung and livers of NNK-treated wild-type and AGT knockout micea [88].
pmol adducts/μmol guanine
AGT status lung liver
O6-mG 24h 4 weeks 24h 4 weeks
Wildtype 42 ±12 55 ±91 7 ±11 5.3 ±0.7
Knockout 65 ±19 110 ±20 210 ±110 380 ±80b
O6-pobG
Wildtype 1.7 ±0.50 .8 ±0.21 .4 ±0.5 ≤0.3
Knockout 2.9 ±0.62 .5 ±0.32 .7 ±1.24 .9 ±1.4
aMice received either a single dose of NNK (∼250mg/kg) and sacriﬁced 24h postinjection or three weekly doses of NNK (∼250mg/kg each week) and
sacriﬁced 1 week after the third treatment. Numbers represent the average of ﬁve samples ±SD.
bThree samples ± SD. Two other samples were analyzed and these two animals had O6-mG levels of 26 and 31pmol O6-mG/μmol guanine. The liver 7-mG
adduct levels for all ﬁve animals were similar: 134 ±17pmol 7-mG/μmol guanine.
agent, NNKOAc [87]. This observation diﬀers starkly from
that observed with methylating agents where the toxicity
of a methylating agent is markedly reduced when AGT is
expressed [87]. Similar results were observed in CHO cells;
AGT expression only minimally reduced the cytotoxicity of
NNKOAc while repairing almost 100% of the O6-pobdG
formed by this pyridyloxobutylating agent [67]. The reduced
toxicity of O6-pobdG may cause it to more greatly contribute
to the overall mutagenic activity of a pyridyloxobutylating
agent since cell death protects against the mutagenic activity
of DNA alkylating agents.
5.5. In Vivo Repair. For both NNK and NNN, the relative
distribution of the four pyridyloxobutyl DNA adducts in
tissuesfromexposedratswassigniﬁcantlydiﬀerentfromthat
observed in DNA treated with a model pyridyloxobutylating
agent in vitro [56, 57, 59–61]. This diﬀerence likely results
from the active repair of speciﬁc adducts. Further support
for this hypothesis is the observed tissue variation in relative
adduct distribution [57, 59–61].
One adduct that appears to be well-repaired in vivo is
O6-pobdG [56, 57, 59–61] .T h el e v e l so ft h i sa d d u c ta r e
very low relative to the other adducts (Tables 1 and 2).
In NNK-treated animals, the levels of O6-mG were much
greater than the levels of O6-pobdG and in the range of the
other pyridyloxobutyl DNA adducts [58]. This observation
suggests that the larger adduct, O6-pobdG, is more readily
repaired than O6mG in vivo.A G Ti so n ep a t h w a yc l e a r l y
responsiblefortherepairofO6-pobdGinvivo[54].However,
other repair pathways may also be involved since this adduct
doesnotaccumulateinlungsofAGTknockoutmicewhereas
O6-mG does (Table 3)[ 88]. This conclusion is further
supported by data in wild-type mice which indicates that
AGTisinactivatedinmouselungfollowingexposuretoNNK
[89].
The most persistent adduct in vivo is O2-pobdT [56, 57,
59–61]. This adduct is a minor adduct in the absence of
repair (7-pobG >O 6-pobdG >O 2-pobdT ≥ O2-pobC) [46].
This is somewhat surprising since this adduct is repaired by
NER in cell line models [67]. A recent study indicated that
NER is reduced in the lungs of NNK-treated mice providing
an explanation for the persistence of this adduct in vivo [90].
The mechanism of this reduction is unknown.
6. Mutagenic Activityof Pyridyloxobutyl
DNA Adducts
Pyridyloxobutylating agents are mutagenic in a variety of
test systems [67, 87, 91, 92]. However, our knowledge of
which pyridyloxobutyl adducts are causing mutations is
still rudimentary. Site-speciﬁc mutagenesis studies have only
been performed for one adduct, O6-pobdG [93]. In bacteria,
it produces exclusively GC to AT transitional mutations.
In human kidney cell line 293 cells, it produces primarily
GC to AT transitional mutations with some GC to TA
transversions and deletions as well as a number of more
complex mutations.
A few studies have begun to link the overall muta-
genic activity of pyridyloxobutyl DNA damage to speciﬁc
adducts through exploring the impact of various DNA
repair pathways on the mutagenic properties of the model
pyridyloxobutylating agent, NNKOAc. The earliest studies
were performed in bacteria. NNKOAc is mutagenic in
Salmonella typhimurium tester strains TA100, TA1535, and
TA98, but not TA102 [92]. Reversion of TA100 and TA1535
requires mutations at a GC base pair and reversion of TA98
requires a frameshift mutation near a CG base pair [94].
TA102 has an AT base pair at the site of reversion [94]. Based
on these observations, it was concluded that pyridyloxobutyl
DNA adducts formed at GC base pairs were mutagenic, at
least in bacteria. However, we cannot rule out that adducts
at AT base pairs are not mutagenic in this study since TA102
has an active NER system [94] that could be repairing any
mutagenic adducts at AT base pairs. TA100, TA1535, and
TA98 lack UvrB and, as a result, do not have an functional
NER system [94].
One candidate adduct for the mutagenicity observed in
TA100 and TA1535 is O6-pobdG. This adduct is poorlyJournal of Nucleic Acids 7
repaired by bacterial AGT [66]. Consistent with its possible
role in NNKOAc-induced mutagenicity is the observation
that the mutagenic activity of NNKOAc was reduced by
roughly 80% in bacteria expressing human AGT [87]. These
studies were performed in S. typhimurium strain YG7108
which is a derivative of TA1535 that lacks both bacterial AGT
genes, ada and ogt [95]. Since the levels of O6-pobdG were
reduced in the strain expressing human AGT by about 66%
[87], these data are consistent with the hypothesis that O6-
pobdG is a signiﬁcant contributor to the mutagenic activity
of pyridyloxobutylating agents at GC base pairs. Other
contributors may include O2-pobC and 7-pobG. However,
these two adducts are not substrates for human AGT.
NNKOAc also induced mutations in the hprt gene
in Chinese hamster ovary (CHO) cells [67]. Analysis of
the mutational spectrum indicated that the bulk of the
mutations occurred at AT base pairs [67]. Most of the AT
mutations were AT to CG transversion mutations. There
were also a small portion of AT to TA transversions and
AT to GC transitional mutations. Approximately 20% of the
mutations were at GC base pairs with the majority of these
being GC to AT transitional mutations.
Loss of NER through ERCC-2 mutation results in an
increase in mutation frequency induced by NNKOAc in
CHO cells [67]. This loss reduced the rate of O2-pobdT
repair in these cells. In addition, there was a corresponding
increase in the frequency of AT to TA mutations relative to
the control cell line. Therefore, it is likely that O2-pobdT
triggers AT to TA mutations. This conclusion is supported
by the observation that another O2-alkyl-2 -deoxythymidine
adduct, O2-ethyl-2 -deoxythymidine, also induces AT to TA
mutations [96]. Loss of BER through loss of XRCC1 also led
to an increase in AT to TA mutations [67], suggesting that
this repair pathway is involved in repair of pyridyloxobutyl
DNA damage at AT base pairs. One possibility is that O2-
pobdT is a substrate for BER glycosylases and the result
abasic sites are responsible for observed increase in AT to TA
mutations observed in the cells lacking BER. This hypothesis
is supported by the report that site-speciﬁcally incorporated
abasic sites primarily induce transversion mutations with
AT to TA mutations being more abundant than AT to GC
mutations [97].
Expression of human AGT in CHO cells did not
signiﬁcantly impact the mutation frequency of NNKOAc
[67]. However, mutations at GC base pairs represented
only approximately 20% of the detected mutations. There
was a reduction in the GC to AT mutations in these cells
but this reduction did not signiﬁcantly aﬀect the mutation
frequency. Since there was almost complete repair of O6-
pobdG, these data support the hypothesis that O6-pobdG is
responsiblefortheGCtoATtransitionalmutationstriggered
by pyridyloxobutyl DNA adducts.
In vivo studies investigating the mutagenic properties
of the pyridyloxobutylation pathway are limited. Mutations
were observed in the 12th codon of K-ras in lung tumors
of A/J mice receiving multiple doses of NNKOAc [98].
Since these mutations were GC to AT transitions and
GC to TA transversions, it is likely that O6-pobdG is
responsible, in part, for these mutations. Both NNK and
NNN have been shown to be mutagenic in target tissues in
lacZa n dlacI transgenic mice [88, 99–101]. The resulting
transgene mutation spectra have only been reported for
NNK [88, 101]. NNK induced an increased rate of GC to
A Tt r a n s i t i o n a lm u t a t i o n sa tn o n - C p Gs i t e sa sw e l la sA T
to TA transitional mutations and a mixture of transversion
mutations (AT to GC, AT to CG, GC to CG, and GC to TA).
Since NNK both methylates and pyridyloxobutylates DNA,
it is diﬃcult to associate speciﬁc mutations with speciﬁc
adducts. However, it is clear that the mutational spectrum is
substantiallymorecomplicatedthanthatobservedforsimple
methylating nitrosamines like dimethylnitrosamine, which
primarily induces GC to AT transitional mutations at non-
CpG sites [102–104].
Collectively, the data presented above indicate that
there are several mutagenic DNA adducts formed upon
pyridyloxobutylation of DNA. These include O6-pobdG and
O2-pobdT. Other adducts likely contribute as well. Which
adducts contribute to the carcinogenic properties of this
pathway are likely to depend on the biological system. If
mutations at AT base pairs are required to produce proteins
with oncogenic function, the formation of O2-pobdT and
its repair is probably important for tumor initiation by this
pathway. On the other hand, if mutations at GC base pairs
areimportantfortriggeringthecarcinogenicprocess,thefor-
mation and persistence of O6-pobdG will be linked to tumor
formation. For example, GC to AT and GC to TA mutations
were observed in the 12th codon of K-ras in lung tumors of
A/JmicereceivingmultipledosesofNNKOAc[98].Itislikely
that O6-pobdG is responsible, in part, for these mutations.
Future studies are required to better deﬁne the toxicological
properties of all pyridyloxobutyl adducts and to determine
the repair pathways responsible for protecting against their
genotoxic eﬀects. An understanding of these fundamental
biochemical issues may help in understanding the individual
diﬀerences in susceptibility to lung cancer risk associated
with tobacco use.
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